The MelNet Executive Committee would like to thank their sponsorship partners whose support has made the sixth New Zealand Melanoma Summit possible.
Sponsorship opportunities are still available. For more information please contact:
Events and Communications Coordinator
Melanoma Network of New Zealand Incorporated
+64 21 139 9670
Merck Sharp & Dohme (New Zealand) Limited (MSD) is a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. MSD was established in New Zealand in 1962.
In New Zealand, MSD provides medicines, vaccines and biologic therapies across a broad range of therapeutic areas. These include; oncology, anaesthesia, HIV/AIDS, antibacterials/antifungals and immunisations.
MSD is one of the few pharmaceutical companies still conducting clinical trials in New Zealand and as at June 2020 invested approximately $NZ78 million in local clinical research. Current research programs include oncology, infectious diseases, endocrinology, chronic cough and vaccines.
Melanoma New Zealand champions the prevention, detection and treatment of melanoma for all New Zealanders. The charity provides the public and patients with information about all aspects of melanoma, encourages sunsmart behaviour, promotes regular skin checks for early detection, and provides patient support, including advocating for increased access to clinical care.